• 1. Excited state dynamics of symmetric and asymmetric Cr3(dpa)4Cl2 measured using femtosecond transient absorption spectroscopy?
  Chao-Han Cheng,Wen-Zhen Wang,Shie-Ming Peng,I-Chia Chen Phys. Chem. Chem. Phys., 2017,19, 25471-25477
• 2. Exceptionally high temperature spin crossover in amide-functionalised 2,6-bis(pyrazol-1-yl)pyridine iron(ii) complex revealed by variable temperature Raman spectroscopy and single crystal X-ray diffraction?
  Max Attwood,Hiroki Akutsu,Lee Martin,Toby J. Blundell,Pierre Le Maguere,Scott S. Turner Dalton Trans., 2021,50, 11843-11851
• 3. Estimates of hydride ion stability in condensed systems: energy of formation and solvation in aqueous and polar-organic solvents
  Craig A. Kelly,David R. Rosseinsky Phys. Chem. Chem. Phys., 2001,3, 2086-2090
• 4. Fast synthesis of copper nanoclusters through the use of hydrogen peroxide additive and their application for the fluorescence detection of Hg2+ in water samples?
  Liao Xiaoqing,Li Ruiyi,Li Zaijun,Sun Xiulan,Wang Zhouping,Liu Junkang New J. Chem., 2015,39, 5240-5248
• 5. Enabling high-throughput single-animal gene-expression studies with molecular and micro-scale technologies
  Jason Wan Lab Chip, 2020,20, 4528-4538

Compound CAS No. 71939-51-0: A Comprehensive Overview of a-Artemether

a-Artemether, identified by the CAS Registry Number 71939-51-0, is a highly potent antimalarial compound that has revolutionized the treatment of malaria, particularly in regions where resistance to traditional antimalarials has become a significant challenge. Derived from the natural compound artemisinin, which is extracted from the plant Artemisia annua, a-Artemether represents a synthetic derivative that enhances the pharmacokinetic properties of its parent compound. This compound has been extensively studied and utilized in various formulations, including injectable and oral preparations, to combat Plasmodium falciparum and other malaria-causing parasites.

The discovery and development of a-Artemether marked a significant milestone in antimalarial chemotherapy. Its unique structure, characterized by an endoperoxide bridge, is responsible for its potent activity against malaria parasites. Recent studies have highlighted the compound's ability to not only target the erythrocytic stage of the parasite but also exhibit activity against gametocytes, thereby reducing transmission potential. This dual mechanism of action makes a-Artemether an invaluable tool in malaria control programs worldwide.

One of the most notable advancements in the use of a-Artemether is its incorporation into fixed-dose combinations with other antimalarials, such as lumefantrine, to form highly effective artemisinin-based combination therapies (ACTs). These combinations have significantly reduced treatment failure rates and contributed to the decline in malaria-related mortality in endemic regions. Recent clinical trials have demonstrated that such combinations not only enhance efficacy but also improve patient compliance due to their convenience and tolerability.

Beyond its antimalarial applications, emerging research has explored the potential of a-Artemether in other therapeutic areas. Preclinical studies suggest that it may exhibit anti-inflammatory and immunomodulatory properties, making it a candidate for treating inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease. Additionally, investigations into its anti-cancer properties have revealed promising results, particularly in targeting drug-resistant cancer cells through mechanisms that involve oxidative stress induction and apoptosis.

The production and scalability of a-Artemether have also been subjects of intense research. Traditional extraction methods from Artemisia annua are limited by variability in crop yield and extraction efficiency. To address this, synthetic pathways have been developed to produce a-Artemether semi-synthetically or entirely through chemical synthesis. These advancements ensure a more reliable supply chain and reduce dependence on agricultural factors, which is crucial for meeting global demand.

In terms of safety profile, extensive toxicological studies have confirmed that a-Artemether strong> is well-tolerated at therapeutic doses. However, ongoing research continues to monitor long-term safety profiles, particularly in vulnerable populations such as children and pregnant women. Recent studies have focused on optimizing dosing regimens to minimize adverse effects while maintaining efficacy.

The global health community has recognized the critical role of a-Artemether strong> in combating malaria, with organizations like the World Health Organization (WHO) endorsing its use as part of first-line treatments for uncomplicated malaria. The compound's inclusion in essential medicines lists underscores its importance in public health strategies aimed at achieving malaria eradication goals.

In conclusion, CAS No. 71939-51-0 (< strong >a-Artem ether< / strong >) stands as a testament to scientific innovation in tropical medicine. Its versatility across therapeutic applications and continued evolution through cutting-edge research position it as a cornerstone in global health initiatives against infectious diseases. As research into its mechanisms of action and potential new indications progresses, the significance of this compound is expected to grow further, offering hope for millions affected by malaria and other debilitating conditions.

• 71939-50-9(Dihydroartemisinin)
• 75887-54-6(Artemotil)
• 81496-81-3(alpha-Dihydroartemisinin)
• 81496-82-4(Dihydroartemisinin)
• 82534-75-6(α-Arteether)
• 93787-85-0(Artemether-d3)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)